University of Virginia-Main Campus · PhysiologyThe Prostate Therapeutics Lab
John Hackett Bushweller · Charlottesville, Virginia
Research Focus
John Hackett Bushweller's lab focuses on developing new treatments for prostate cancer, particularly by designing small molecule inhibitors that target the ERG transcription factor, which plays a crucial role in the development and progression of this disease. The research aims to enhance the effectiveness of existing therapies and address the problem of drug resistance in patients. Through biochemical and cellular assays, the lab seeks to optimize these inhibitors and evaluate their effects on cancer biology, potentially leading to improved patient outcomes.
prostate cancersmall molecule inhibitorstranscription factorsdrug resistanceanticancer therapeutics
Research Aims
5AIM 01Optimize small molecule inhibitors of the ERG transcription factor.
AIM 02Evaluate the potency and selectivity of ERG inhibitors on prostate cancer cells.
AIM 03Profile the effects of ERG inhibitors on gene expression.
AIM 04Test inhibitors on patient-derived xenografts of prostate cancer.
AIM 05Develop new therapeutic strategies for castration-resistant prostate cancer.
Skills the Lab Values
cell culturebiochemical assaysmass spectrometrygenome-wide profilinggene expression analysis
Output against the department
Publications193top 35% of dept.100th of 286
this lab
most publishedleast published
Citations9.2ktop 37% of dept.105th of 286
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.